Economic Burden of Acute Coronary Syndromes
Author Information
Author(s): Zhao Zhenxiang, Winget Melissa
Primary Institution: Eli Lilly and Company
Hypothesis
The study aims to evaluate the medical and productivity costs associated with acute coronary syndromes (ACS) based on different treatment strategies.
Conclusion
The study found that both total 1-year medical costs and productivity costs are substantial for working-aged individuals with ACS, with CABG patients incurring the highest costs.
Supporting Evidence
- The total 1-year medical costs were lowest for MM patients at $34,087.
- CABG patients had the highest 1-year productivity costs at $17,335 for short-term disability.
- The study utilized a large claims database to analyze costs associated with ACS.
Takeaway
This study shows that getting treated for heart problems can be very expensive, especially if you have surgery. Some treatments cost a lot more than others.
Methodology
The study analyzed claims data from commercially insured individuals aged 18-64 who had an ACS diagnosis, categorizing them into three treatment groups: medical management, PCI, or CABG.
Potential Biases
Potential for miscoding of medical claims and missing data.
Limitations
The study's retrospective design may lead to issues with data accuracy, and results may not be generalizable to populations outside of working-age individuals with employer-sponsored insurance.
Participant Demographics
Patients aged 18-64, with a mean age of 54.3 for MM, 54.8 for PCI, and 56.5 for CABG; gender distribution varied across treatment groups.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI: $36,332-$41,702 for MM, $54,972-$61,653 for PCI, $85,044-$98,910 for CABG
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website